Source link : https://www.newshealth.biz/health-news/alectinib-approved-for-alk-positive-adjuvant-nsclc/
The US Food and Drug Administration (FDA) has approved alectinib (Alecensa, Genentech) in the adjuvant setting following tumor resection in patients with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test. “Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have […]
Author : News Health
Publish date : 2024-04-22 08:45:32
Copyright for syndicated content belongs to the linked Source.
in Health